IP Library Granted Patent US 10,370,447
Granted Patent B2
US 10,370,447 · App. 15/326,501 · Granted Aug 6, 2019

Molecules with specificity for CD79 and CD22

Inventors: Helene Margaret Finney (Slough, GB); Stephen Edward Rapecki (Slough, GB); Michael John Wright (Slough, GB); Kerry Louise Tyson (Slough, GB)
Assignee: UCB BIOPHARMA SPRL
C07K16/2803C07K16/18A61K2039/505C07K2317/24C07K2317/31C07K2317/35C07K2317/55C07K2317/622C07K2317/624C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,370,447
App. No.
15/326,501
Granted
Aug 6, 2019
Kind
B2
Abstract

The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.

Claims (18)

1. A multispecific molecule comprising a binding domain specific to human antigen CD22 and a binding domain specific to human antigen CD79b,

wherein the binding domain specific to human antigen CD22 comprises 3 heavy chain CDRs comprising SEQ ID NO: 128 for CDRH1, SEQ ID NO: 129 for CDRH2 and SEQ ID NO: 130 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 125 for CDRL1, SEQ ID NO: 126 for CDRL2 and SEQ ID NO: 127 for CDRL3; or

comprises 3 heavy chain CDRs comprising SEQ ID NO: 138 for CDRH1, SEQ ID NO: 139 wherein the Cys has been replaced by Ser for CDRH2 and SEQ ID NO: 140 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 135 for CDRL1, SEQ ID NO: 136 for CDRL2 and SEQ ID NO: 137 for CDRL3; and

wherein the binding domain specific to human CD79b comprises 3 heavy chain CDRs comprising specific for CD79b and comprises 3 heavy chain CDRs comprising SEQ ID NO: 78 for CDRH1, SEQ ID NO: 79 for CDRH2 and SEQ ID NO: 80 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 75 for CDRL1, SEQ ID NO: 76 for CDRL2 and SEQ ID NO: 77 for CDRL3; or

3 heavy chain CDRs comprising SEQ ID NO: 78 for CDRH1, SEQ ID NO: 79 for CDRH2 and SEQ ID NO: 80 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 85 for CDRL1, SEQ ID NO: 86 for CDRL2 and SEQ ID NO: 87 for CDRL3; or

3 heavy chain CDRs comprising SEQ ID NO: 88 for CDRH1, SEQ ID NO: 89 for CDRH2 and SEQ ID NO: 90 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 85 for CDRL1, SEQ ID NO: 86 for CDRL2 and SEQ ID NO: 87 for CDRL3; or

3 heavy chain CDRs comprising SEQ ID NO: 88 for CDRH1, SEQ ID NO: 89 for CDRH2 and SEQ ID NO: 90 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 75 for CDRL1, SEQ ID NO: 76 for CDRL2 and SEQ ID NO: 77 for CDRL3.

2. The multispecific molecule according to claim 1 , wherein the molecule is bispecific.

3. The multispecific molecule according to claim 1 , wherein the molecule is a fusion protein.

4. The multispecific molecule according to claim 1 , wherein the molecule format is selected from diabody, scdiabody, triabody, tandem scFv, FabFv, Fab′Fv, FabdsFv, Fab-scFv, Fab-dsscFv, Fab-(dsscFv) 2 , diFab, diFab′, tribody, tandem scFv-Fc, scFv-Fc-scFv, scdiabody-Fc, scdiabody-CH3, Ig-scFv, scFv-Ig, V-Ig, Ig-V, Duobody and DVD-Ig.

5. The multispecific molecule according to claim 1 , wherein each binding domain is monospecific.

6. The multispecific molecule according to claim 1 , wherein the multispecific molecule comprises no more than one binding domain which is specific to CD22 and no more than one binding domain which is specific to CD79b.

7. The multispecific molecule according to claim 1 , wherein the binding domain which is specific to CD22 and the binding domain which is specific to CD79a andler CD79b are independently selected from a Fab, scFv, Fv, dsFv and dsscFv.

8. The multispecific molecule according to claim 1 , in which the binding domains are humanised.

9. The multispecific molecule according to claim 1 , which further comprises a binding domain specific to serum albumin.

10. A composition comprising one or more multispecific molecules as defined in claim 1 and a pharmaceutically acceptable excipient, diluent or carrier.

11. A multispecific molecule comprising a binding domain specific to human antigen CD22 and a binding domain specific to human antigen CD79b, wherein the binding domain specific to human antigen CD22 comprises 3 heavy chain CDRs comprising SEQ ID NO: 138 for CDRH1, SEQ ID NO: 139, wherein Cys has been replaced by Ser for CDRH2 and SEQ ID NO: 140 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 135 for CDRL1, SEQ ID NO: 136 for CDRL2and SEQ ID NO: 137 for CDRL3; and

wherein the binding domain specific to human CD79b comprises 3 heavy chain CDRs comprising SEQ ID NO: 88 for CDRH1, SEQ ID NO: 89 for CDRH2 and SEQ ID NO: 90 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 85 for CDRL1, SEQ ID NO: 86 for CDRL2 and SEQ ID NO: 87 for CDRL3.

Assignments (2)
CHANGE OF NAME Recorded Dec 15, 2021
From: UCB BIOPHARMA SPRL
To: UCB BIOPHARMA SRL
Reel/Frame 058520/0130 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2017
From: FINNEY, HELENE MARGARET; RAPECKI, STEPHEN EDWARD; WRIGHT, MICHAEL JOHN; TYSON, KERRY LOUISE
To: UCB BIOPHARMA SPRL
Reel/Frame 041202/0773 →
Priority Claims (1)
GB 1412658.5 · Jul 16, 2014 · national
Continuity (1)
Related Publication 20170204178A1 · Jul 20, 2017
Cited By (2)
US 12,247,071 US 12,331,117